Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 3, 2011, Pages 551-555

  Escaff, Safwan ^a   Fernández, Jesús M ^b   González, Luis O ^a   Suárez, Aurelio ^a   González Reyes, Salomé ^a   González, José M ^a   Vizoso, Francisco J ^a  

^a HOSPITAL DE JOVE   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

MMP; Prognosis; Prostate carcinoma; PSA; Tissue arrays; Tumour invasion

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STROMA CELL;

AGED; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; STROMAL CELLS; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 79954446489     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0906-8     Document Type: Article

References (22)

1. Bhowmick NA, Moses HL (2005) Tumor-stroma interactions. Curr Opin Genet Dev 15:97-101 (Pubitemid 40127637)
2. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO (2005) Anatomic distribution and pathologic characterization of smallvolume prostate cancer (< 0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 18:1022-1026 (Pubitemid 41224491)
3. Cornelius LA, Nehring LC, Harding E et al (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161:6845-6852 (Pubitemid 28562229)
4. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174 (Pubitemid 37328786)
5. Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. Jama 271:368-374 (Pubitemid 24037911)
6. Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM (2001) Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3:459-468 (Pubitemid 33151012)
7. Goodson WH III, Ljung BM, Moore DH II et al (1993) Tumor labeling indices of primary breast cancers and their regional lymph node metastases. Cancer 71:3914-3919 (Pubitemid 23172969)
8. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J (2005) Molecular pathology of prostate cancer. J Clin Pathol 58:673-684 (Pubitemid 40956818)
9. Jiang Y, Goldberg ID, Shi YE (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21:2245-2252 (Pubitemid 34311378)
10. Jones JL, Walker RA (1997) Control of matrix metalloproteinase activity in cancer. J Pathol 183:377-379
11. Kim JB, Stein R, O'Hare MJ (2005) Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol 26:173-185 (Pubitemid 41379743)
12. Liu N, Lapcevich RK, Underhill CB et al (2001) Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res 61:1022-1028 (Pubitemid 32174420)
13. Manes S, Llorente M, Lacalle RA et al (1999) The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274:6935-6945
14. Marberger M, Carroll PR, Zelefsky MJ et al (2008) New treatments for localized prostate cancer. Urology 72: S36-S43
15. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135-1149 (Pubitemid 30123793)
16. Noel A, Boulay A, Kebers F et al (2000) Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 19:1605-1612 (Pubitemid 30175683)
17. Parker RL, Huntsman DG, Lesack DW et al (2002) Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 117:723-728 (Pubitemid 34457006)
18. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916 (Pubitemid 17147932)
19. Stetler-Stevenson WG (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103:1237-1241 (Pubitemid 29218293)
20. Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol 1:119-150
21. Turk V, Kos J, Turk B (2004) Cysteine cathepsins (proteases)-on the main stage of cancer? Cancer Cell 5:409-410 (Pubitemid 38610242)
22. Wurtz SO, Schrohl AS, Sorensen NM et al (2005) Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 12:215-227 (Pubitemid 40903085)